Hospitalization in adults aged 75 years and older with type 2 diabetes: The role of kidney impairment and glycemic control
Abstract
Abstract Background Older adults aged ≥ 75 years with type 2 diabetes (T2D) experience high healthcare utilization, yet evidence on treatment patterns and outcomes in this age group is limited. Objective To assess associations between glycemic control, kidney function, and hospitalization among individuals aged ≥ 75 years with T2D. Methods Individuals aged ≥ 75 years with T2D were identified in 2018 using data from a population‑based healthcare database covering all levels of care in Region Halland. Healthcare utilization, including hospital admissions, hospital days, primary care encounters and mortality, was evaluated during 2019. Inclusion required at least one measurement of glycated hemoglobin (HbA1c) and estimated glomerular filtration rate (eGFR). Kidney function was classified by eGFR ≥ 60; 30–59; 70 mmol/mol. Associations with hospital days were analyzed using Poisson regression adjusted for demographic, clinical, and treatment variables. Results The cohort comprised 1,446 individuals (49% women); 88 patients (6%) died during follow‑up. HbA1c was 70 mmol/mol in 12%. CKD was common, with 56% classified as stage 3 and 10% as stage 4–5. Hospital days were higher among individuals with CKD stage 4–5 (RR 1.93, 95% CI:1.71–2.17) and HbA1c > 70 mmol/mol (RR 1.44, 95% CI:1.28–1.61). Primary care encounters were frequent (physician visits: 4.6 [SD 3.7]; nurse visits: 9.0 [SD 9.3]) and associated with CKD but not with glucose dysregulation. Insulin use was associated with…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 1,446 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.